Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:CRVO NASDAQ:HOTH NASDAQ:RPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.51-1.6%$0.44$0.30▼$10.62$73.68M2.062.53 million shs1.01 million shsCRVOCervoMed$10.69+5.8%$8.37$1.80▼$20.63$98.88M-0.721.94 million shs168,393 shsHOTHHoth Therapeutics$1.33+3.9%$1.28$0.65▼$3.80$17.64M0.673.93 million shs2.80 million shsRPTXRepare Therapeutics$1.72+1.2%$1.53$0.89▼$4.07$73.89M0.94297,341 shs91,084 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics+5.56%-2.51%+18.02%+38.55%-91.80%CRVOCervoMed+4.99%+5.65%+14.38%+35.03%-45.76%HOTHHoth Therapeutics+10.34%+4.07%-1.92%-16.34%+84.46%RPTXRepare Therapeutics+1.80%+5.59%+13.33%+17.24%-41.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.1425 of 5 stars3.33.00.04.72.41.70.6CRVOCervoMed3.2294 of 5 stars3.44.00.00.03.51.70.6HOTHHoth Therapeutics2.6179 of 5 stars3.55.00.00.01.60.00.6RPTXRepare Therapeutics3.3567 of 5 stars3.35.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,092.34% UpsideCRVOCervoMed 2.78Moderate Buy$23.71121.84% UpsideHOTHHoth Therapeutics 3.00Buy$4.00200.75% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50161.63% UpsideCurrent Analyst Ratings BreakdownLatest HOTH, APLT, RPTX, and CRVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $31.008/18/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.008/12/2025CRVOCervoMedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.008/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $15.008/11/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.007/30/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.007/29/2025CRVOCervoMedCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $27.007/25/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/23/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/26/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$121K608.90N/AN/A$0.12 per share4.26CRVOCervoMed$9.74M10.15N/AN/A$3.61 per share2.96HOTHHoth TherapeuticsN/AN/AN/AN/A$0.73 per shareN/ARPTXRepare Therapeutics$53.48M1.38N/AN/A$2.57 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.45N/AN/AN/AN/A-354.24%-144.16%11/6/2025 (Estimated)CRVOCervoMed-$16.29M-$2.61N/AN/AN/A-290.72%-59.15%-53.64%11/11/2025 (Estimated)HOTHHoth Therapeutics-$8.19M-$1.07N/AN/AN/AN/A-114.32%-105.92%11/11/2025 (Estimated)RPTXRepare Therapeutics-$84.69M-$2.58N/AN/AN/AN/A-78.25%-66.85%11/6/2025 (Estimated)Latest HOTH, APLT, RPTX, and CRVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025APLTApplied Therapeutics-$0.17-$0.15+$0.02-$0.15$0.42 millionN/A8/12/2025Q2 2025HOTHHoth Therapeutics-$0.27-$0.17+$0.10-$0.17N/AN/A8/8/2025Q2 2025CRVOCervoMed-$0.57-$0.70-$0.13-$0.70$1.45 million$1.76 million8/8/2025Q2 2025RPTXRepare Therapeutics-$0.56-$0.39+$0.17-$0.39$2.50 million$0.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.941.94CRVOCervoMedN/A8.208.20HOTHHoth TherapeuticsN/A27.5427.54RPTXRepare TherapeuticsN/A6.306.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CRVOCervoMed25.15%HOTHHoth Therapeutics7.08%RPTXRepare Therapeutics85.09%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%CRVOCervoMed35.40%HOTHHoth Therapeutics6.92%RPTXRepare Therapeutics11.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30144.01 million141.71 millionOptionableCRVOCervoMed49.25 million5.98 millionNot OptionableHOTHHoth Therapeutics413.26 million12.34 millionNot OptionableRPTXRepare Therapeutics18042.96 million38.02 millionOptionableHOTH, APLT, RPTX, and CRVO HeadlinesRecent News About These CompaniesRepare Therapeutics Announces Licensing Deal and Strategic UpdatesAugust 12, 2025 | theglobeandmail.comRepare Therapeutics (NASDAQ:RPTX) Posts Earnings ResultsAugust 11, 2025 | marketbeat.comRepare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street ZenAugust 10, 2025 | marketbeat.comRepare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2025 | zacks.comRepare (RPTX) Q2 Loss Narrows 52%August 8, 2025 | fool.comRepare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | financialpost.comFRepare Therapeutics Jumps 15% After $10M Licensing Deal With DebiopharmJuly 18, 2025 | uk.finance.yahoo.comRepare Therapeutics Inc. (RPTX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comRepare inks licensing deal with Debiopharm for lunresertibJuly 16, 2025 | thepharmaletter.comTRepare finds suitor for paused PKMYT1 inhibitor in current partner DebiopharmJuly 16, 2025 | fiercebiotech.comFRepare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush InJuly 16, 2025 | msn.comRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | businesswire.comRepare Therapeutics Inc (RPTX) - Investing.comJuly 3, 2025 | investing.comRepare Therapeutics Inc (RPTX) Stock Forums - Investing.comJune 30, 2025 | investing.comRepare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic DealJune 25, 2025 | insidermonkey.comRepare Therapeutics Updates Severance Benefits for ExecutivesJune 20, 2025 | tipranks.comRepare Therapeutics Strengthens Leadership with New Executive AppointmentJune 2, 2025 | tipranks.comRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOTH, APLT, RPTX, and CRVO Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.51 -0.01 (-1.63%) Closing price 04:00 PM EasternExtended Trading$0.50 -0.01 (-1.68%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.CervoMed NASDAQ:CRVO$10.69 +0.59 (+5.84%) Closing price 04:00 PM EasternExtended Trading$10.56 -0.13 (-1.17%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Hoth Therapeutics NASDAQ:HOTH$1.33 +0.05 (+3.91%) Closing price 04:00 PM EasternExtended Trading$1.33 0.00 (0.00%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Repare Therapeutics NASDAQ:RPTX$1.72 +0.02 (+1.18%) Closing price 04:00 PM EasternExtended Trading$1.69 -0.03 (-1.74%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
